Skip to main content
Premium Trial:

Request an Annual Quote

Genomind Genecept Assay

Genomind has launched a new, expanded version of its Genecept Assay, a pharmacogenetic test to help guide psychiatric treatment. The company has added eight more genes to its existing panel of 10, based on a meta-analysis of hundreds of published studies showing that variations in these genes can inform decisions for psychiatric treatment. The test now covers chronic pain and substance abuse, as well as depression, anxiety, obsessive-compulsive disorder, attention-deficit hyperactivity disorder, bipolar disorder, post-traumatic stress disorder, autism and schizophrenia. It also covers more than 15 drug classes, 103 FDA-approved medications, and 97 percent of drugs used to treat depression, anxiety, bipolar disorder, schizophrenia, attention-deficit disorder, autism, and pain disorders.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.